Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS.IL)

50,90 +0,83 (+1,66%) Alla chiusura: 04:49PM BST

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 4.300

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Robert Koremans M.D.	CEO & Director	1,81M	N/D	1962
Mr. Luigi Felice La Corte	Group CFO & Exec. Director	948k	N/D	1969
Ms. Cathrin Petty	Exec. Director	N/D	N/D	1973
Mr. Giampiero Mazza	Exec. Director	N/D	N/D	1969
Mr. Giorgio De Palma	Exec. Director	N/D	N/D	1974
Ms. Federica De Medici	Director of Investor Relations & Corp. Communications	N/D	N/D	N/D
Ms. Bibianne Bon	Group Chief Legal Officer	N/D	N/D	N/D
Mr. Gabriele Finzi	Exec. VP of Corp. Devel., Licensing & Innovation	N/D	N/D	N/D
Mr. Giuseppe Gualazzini	Sr. VP of Group HR	N/D	N/D	1959
Mr. Roberto Teruzzi	Exec. VP of Group Industrial Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Governance aziendale

L'ISS Governance QualityScore di Recordati Industria Chimica e Farmaceutica S.p.A. al 1 ottobre 2023 è 3. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 3; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.